Can a common asthma drug help newborns breathe easier?
NCT ID NCT07350421
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether inhaled salbutamol, a drug used for asthma, can reduce breathing distress in newborns with transient tachypnea of the newborn (TTN). TTN is a common lung condition after birth where fluid stays in the lungs, causing fast breathing. The trial will enroll just 1 baby born at 36 weeks or later, and will measure breathing scores over 72 hours. It is a very early, small study, so results are uncertain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Salbutamol (Albuterol) by inhalation
- What this could lead to
- If it works, this could point toward a simple treatment to help newborns with TTN breathe easier and leave the hospital sooner.
- What could go wrong
- This is an extremely early trial with only 1 participant, so results may not apply to other babies. The treatment may not improve breathing or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TTN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Latakia University
Latakia, Latakia Governorate, Syria
More trials for these conditions
Other studies related to the condition(s) this trial covers.